By Chris Wack

 

Zai Lab Ltd. shares were up 10% to $50 after the company said its partner, Karuna Therapeutics Inc., reported positive top-line results from its Phase 3 trial evaluating the efficacy, safety and tolerability of its lead investigational therapy, KarXT xanomeline-trospium, in adults with schizophrenia.

Zai Lab has an exclusive license agreement with Karuna Therapeutics for the development, manufacturing, and commercialization of KarXT in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

Karuna Therapeutics said the trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale, or PANSS, total score at the fifth week.

KarXT also showed an early and sustained statistically significant reduction of symptoms, as assessed by PANSS total score, starting at the second week, and maintained the reduction through all time points in the trial, the company said.

The KarXT trial also met secondary endpoints, demonstrating a statistically significant reduction in symptoms of schizophrenia, the company said.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

August 08, 2022 07:48 ET (11:48 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Karuna Therapeutics Charts.
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Karuna Therapeutics Charts.